Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cimetidine disposition in obesity.

D R Abernethy, D J Greenblatt, R Matlis

    The American Journal of Gastroenterology
    |February 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Response to diazepam in sons of alcoholics.

    Alcoholism, clinical and experimental research·1992
    Same author

    Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone.

    Brain research bulletin·1992
    Same author

    Mental illness, pharmacotherapy, and automobile operation: what is the risk?

    Journal of clinical psychopharmacology·1992
    Same author

    Bioavailability studies of drugs with nonlinear pharmacokinetics: I. Tracer dose AUC varies directly with serum concentration.

    Journal of clinical pharmacology·1992
    Same author

    Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs.

    Journal of veterinary pharmacology and therapeutics·1992
    Same author

    Fluoxetine impairs clearance of alprazolam but not of clonazepam.

    Clinical pharmacology and therapeutics·1992
    Same journal

    Calendar of Courses, Symposiums and Conferences.

    The American journal of gastroenterology·2026
    Same journal

    Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

    The American journal of gastroenterology·2026
    Same journal

    ACG Clinical Guideline: Colonic Diverticulitis.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    2026 CME Information.

    The American journal of gastroenterology·2026
    See all related articles

    Cimetidine pharmacokinetics do not significantly differ between obese and normal-weight individuals. Dosage should be based on ideal body weight (IBW) rather than total body weight for accurate dosing.

    Area of Science:

    • Pharmacology
    • Clinical Pharmacology
    • Obesity Medicine

    Background:

    • Obesity affects drug pharmacokinetics, potentially altering drug efficacy and safety.
    • Understanding cimetidine distribution and elimination in obese individuals is crucial for appropriate dosing.

    Purpose of the Study:

    • To investigate cimetidine pharmacokinetics in obese versus normal-weight healthy volunteers.
    • To determine if obesity influences cimetidine's elimination half-life, volume of distribution, and metabolic clearance.

    Main Methods:

    • Pharmacokinetic analysis of cimetidine in 13 obese and 16 normal-weight healthy volunteers.
    • Intravenous administration of cimetidine (200-300 mg) followed by plasma sampling over 24 hours.
    • High-pressure liquid chromatography used to quantify plasma cimetidine concentrations.

    Related Experiment Videos

    Main Results:

    • No significant differences in elimination half-life (2.23 vs. 2.08 h), apparent volume of distribution (120 vs. 106 L), or total metabolic clearance (616 vs. 579 ml/min) were observed between obese and control groups.
    • Cimetidine distribution was similar relative to ideal body weight (IBW), with minimal distribution into excess adipose tissue.
    • No correlation was found between percentage IBW and apparent volume of distribution.

    Conclusions:

    • Obesity does not alter cimetidine's pharmacokinetic profile (half-life, clearance, volume of distribution).
    • Cimetidine dosage should be calculated using ideal body weight (IBW) to account for lean body mass, not total body weight.
    • This approach ensures more accurate and effective cimetidine dosing in obese patients.